-
Your selected country is
Germany
- Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Profile of peripheral blood granulocytes analyzed by flow cytometry
BD Pharmingen™ PE Mouse Anti-Human CD88
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Product Notices
- This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- Source of all serum proteins is from USDA inspected abattoirs located in the United States.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
The D53-1473 monoclonal antibody specifically recognizes CD88, a 40 kDa polypeptide expressed on granulocytes (high), monocytes (low) and macrophages. CD88 is a G type protein-coupled receptor with seven transmembrane domains. It binds to C5a, the α chain of the complement component C5. C5a is cleaved from C5 during complement activation. The binding of C5a to C5a receptor (C5aR, CD88) on granulocytes leads to various effects including shedding of selectins, upregulation of adhesion molecules, chemotaxis, granule exocytosis and activation of NADPH oxidase. Clone D53-1473 was developed using a known C5aR N-terminal extracellular hydrophilic region (a.a. 1-31) peptide as immunogen. This antibody is useful in inflammation and chemotaxis research.
This antibody is routinely tested by flow cytometric analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.
Development References (3)
-
Barclay NA, Brown MH, Birkeland ML, et al, ed. The Leukocyte Antigen FactsBook. San Diego, CA: Academic Press; 1997.
-
Morelli A, Larregina A, Chuluyán I, Kolkowski E, Fainboim L. Expression and modulation of C5a receptor (CD88) on skin dendritic cells. Chemotactic effect of C5a on skin migratory dendritic cells. Immunology. 1996; 89(1):126-134. (Biology). View Reference
-
Morgan EL, Ember JA, Sanderson SD, et al. Anti-C5a receptor antibodies. Characterization of neutralizing antibodies specific for a peptide, C5aR-(9-29), derived from the predicted amino-terminal sequence of the human C5a receptor. J Immunol. 1993; 151(1):377-388. (Biology). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.